Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Cancer Treatment Reviews|January 1, 1993
An overview of experience with TAXOL (paclitaxel) in the U.S.AR C Donehower, E K Rowinsky
Journal of the National Cancer Institute|December 18, 1991
Taxol: twenty years later, the story unfoldsE K Rowinsky, R C Donehower
The New England Journal of Medicine|April 13, 1995
Paclitaxel (taxol)E K Rowinsky, R C Donehower
Seminars in Oncology|August 1, 1993
The clinical pharmacology of paclitaxel (Taxol)E K Rowinsky, R C Donehower
Cancer Chemotherapy and Pharmacology|January 1, 1980
The practical benefits of pharmacokinetics in the use of antineoplastic agentsC Erlichman, R C Donehower, B A Chabner
Investigational New Drugs|April 9, 2001
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinomaS Lakhanpal, R C Donehower, E K Rowinsky
Annals of Internal Medicine|May 1, 1988
Nifedipine and oncologic Raynaud phenomenonA Hantel, E K Rowinsky, R C Donehower
Methods in Enzymology|January 1, 1982
Competitive protein binding assay of methotrexateC Erlichman, R C Donehower, C E Myers
Seminars in Oncology|June 1, 1987
An in vitro model to predict clinical response in adult acute myelogenous leukemiaJ E Karp, R C Donehower, P J Burke
Cancer Treatment Reports|September 1, 1986
Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusionR C Donehower, J E Karp, P J Burke
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Cancer Treatment Reviews|January 1, 1993
An overview of experience with TAXOL (paclitaxel) in the U.S.AR C Donehower, E K Rowinsky
Journal of the National Cancer Institute|December 18, 1991
Taxol: twenty years later, the story unfoldsE K Rowinsky, R C Donehower
The New England Journal of Medicine|April 13, 1995
Paclitaxel (taxol)E K Rowinsky, R C Donehower
Seminars in Oncology|August 1, 1993
The clinical pharmacology of paclitaxel (Taxol)E K Rowinsky, R C Donehower
Cancer Chemotherapy and Pharmacology|January 1, 1980
The practical benefits of pharmacokinetics in the use of antineoplastic agentsC Erlichman, R C Donehower, B A Chabner
Investigational New Drugs|April 9, 2001
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinomaS Lakhanpal, R C Donehower, E K Rowinsky
Annals of Internal Medicine|May 1, 1988
Nifedipine and oncologic Raynaud phenomenonA Hantel, E K Rowinsky, R C Donehower
Methods in Enzymology|January 1, 1982
Competitive protein binding assay of methotrexateC Erlichman, R C Donehower, C E Myers
Seminars in Oncology|June 1, 1987
An in vitro model to predict clinical response in adult acute myelogenous leukemiaJ E Karp, R C Donehower, P J Burke
Cancer Treatment Reports|September 1, 1986
Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusionR C Donehower, J E Karp, P J Burke
Pageof 13